Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.
New trial data showed CagriSema led to 'superior' weight loss, but at a rate less than expectations Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy ...
After 68 weeks, 61.9% of those treated with CagriSema reached the highest dose. Analysis of the study data after 68 weeks, assuming all people adhered to treatment, revealed that a superior weight ...
Investing.com -- Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest clinical trial data for CagriSema, a treatment for adults with ...
New trial data showed CagriSema led to 'superior' weight loss, but at a rate much less than original expectations of 25% Shares of Novo Nordisk A/S were getting hit hard in early Monday trading ...
Novo Nordisk’s investors are unimpressed by Phase III trial data of the weekly injectable weight loss therapy, CagriSema, which fell short of the original 25% weight loss promise despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback